Cellular Reprogramming May Offer Stem-Cell Compromise

President Obama’s recent reversal of Bush’s policy on embryonic stem cell research reignited the debate over the ethical limits of science. However, as the Wall Street Journal reports, an innovative new technique could potentially reproduce the benefits of embryonic stem cells without the attendant controversy.

Read more »

More Good News for AstraZeneca

A new analysis of AstraZeneca’s cholesterol-lowering statin Crestor shows that the drug sharply reduces the risk of venous thromboembolism (VTE), a potentially fatal disorder in which blood clots can form in the legs and travel to the lungs.

Read more »

U.S. Hospitals Slow to Adopt Electronic Medical Records

Only 9 percent of U.S. hospitals use electronic medical records, according to a new survey. It’s a far cry from the comprehensive, high-tech environment supported by the Obama and Bush administrations.

Read more »

Good News for Market-Leading Stent

A new study by Abbott Laboratories found that their drug-coated stent, Xience V, is more effective in the long term than a competitor’s. According to the Wall Street Journal, the data showed that rates of major cardiovascular events plateaued at 6.4% in the second and third years after Xience was implanted.

Read more »